logo

For the Inventor, By the Inventor

Weesp, Netherlands

Hein K A C Coolen

This inventor holds 17 USPTO granted patents. Top assignees: Abbvie B.v., Abbvie Inc., Solvay Pharmaceuticals, B.v.. Active years: 2006-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hein K A C Coolen. Retrieved from https://idiyas.com/inventor/hein-k-a-c-coolen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17

% Patents Active = 52.9

Average Co-Inventor Count = 5.8

ph-index = 3

Forward Citations = 27(Granted Patents)


Location History:

  • Weesp, NL (2006 - 2016)
  • Hoofddorp, NL (2014 - 2022)

Company Filing History:

goldMedal9 out of 13 
 
Abbvie B.v.
 patents
silverMedal7 out of 826 
 
Abbvie Inc.
 patents
bronzeMedal5 out of 67 
 
Solvay Pharmaceuticals, B.v.
 patents
4. 2 out of 6 
 
Abbvie Bahamas Limited
 patents
5. 1 out of 167 
 
Abbvie Deutschland Gmbh and Co Kg
 patents
where one patent can have more than one assignee

Years Active: 2006-2022

Loading Chart...
17 patents (USPTO):Explore Patents
1. 11427598 - Spiro-cyclic amine derivatives as S1P modulators (2022-08-30),
2. RE48301 - Fused heterocyclic derivatives as S1P modulators (2020-11-09),
3. 10807991 - Spiro-cyclic amine derivatives as S1P modulators (2020-10-20),
4. 10179791 - Spiro-cyclic amine derivatives as S1P modulators (2019-01-15),
5. 9951084 - Spiro-cyclic amine derivatives as S1P modulators (2018-04-24),
6. 9670220 - Fused heterocyclic derivatives as S1P modulators (2017-06-06),
7. 9273017 - (Thio)morpholine derivatives as S1P modulators (2016-03-01),
8. 9096612 - Fused heterocyclic derivatives as S1P modulators (2015-08-04),
9. 9045441 - (Thio)morpholine derivatives as S1P modulators (2015-06-02),
10. 8796262 - Fused heterocyclic derivatives as S1P modulators (2014-08-05),
11. 8735388 - Heterocyclic compounds with affinity to muscarinic receptors (2014-05-27),
12. 8586606 - Heterocyclic compounds with affinity to muscarinic receptors (2013-11-19),
13. 8252930 - Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition (2012-08-28),
14. 8084473 - Heterocyclic compounds with affinity to muscarinic receptors (2011-12-27),
15. 7964728 - Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition (2011-06-21),

Title: The Innovative Contributions of Hein K A C Coolen

Introduction

Hein K A C Coolen is a notable inventor based in Weesp, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that modulate S1P receptors. With a total of 17 patents to his name, Coolen's work has the potential to impact the treatment of various diseases.

Latest Patents

Among his latest patents, Coolen has developed spiro-cyclic amine derivatives as S1P modulators. This invention relates to spiro-cyclic amine derivatives of a specific formula, which may be used in the treatment, alleviation, or prevention of diseases involving S1P receptors. Another significant patent involves fused heterocyclic derivatives as S1P modulators. This invention focuses on new fused heterocyclic derivatives that have affinity to S1P receptors and can be used in pharmaceutical compositions for treating conditions related to S1P signaling.

Career Highlights

Coolen has worked with prominent companies in the pharmaceutical industry, including AbbVie B.V. and AbbVie Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Hein K A C Coolen has collaborated with notable colleagues such as Wouter I Iwema Bakker and Axel Stoit. These collaborations have likely enhanced his research and development efforts in the pharmaceutical field.

Conclusion

Hein K A C Coolen's innovative work in the development of S1P modulators showcases his significant contributions to pharmaceutical science. His patents reflect a commitment to advancing medical treatments and improving patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…